References
  1. Giudicessi J, Ackerman M. Azithromycin and risk of sudden cardiac death: Guilty as charged or falsely accused? Cleveland Clinic Journal of Medicine . 2013;80(9):539-544.
  2. Gorelik E, Masarwa R, Perlman A, Rotshild V, Muszkat M, Matok I. Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides. Antimicrobial Agents and Chemotherapy. 2018;62(6).
  3. Polgreen L, Riedle B, Cavanaugh J, Girotra S, London B, Schroeder M et al. Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities. Journal of the American Heart Association . 2018;7(9).
  4. Juurlink D. The cardiovascular safety of azithromycin. Canadian Medical Association Journal . 2014;186(15):1127-1128.
  5. Chico R, Pittrof R, Greenwood B, Chandramohan D. Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy. Malaria Journal . 2008;7(1).
  6. WHO policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP) [Internet]. World Health Organization. 2014 [cited 1 June 2020]. Available from: https://www.who.int/malaria/publications/atoz/policy_brief_iptp_sp_policy_recommendation/en/
  7. Kimani J, Phiri K, Kamiza S, Duparc S, Ayoub A, Rojo R et al. Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial. PLOS ONE . 2016;11(6):e0157045.
  8. Timothy F. Simpson Richard J. Kovacs; Eric C. Stecker. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 - American College of Cardiology [Internet]. American College of Cardiology. 2020 [cited 1 June 2020]. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19
  9. Ridings JE. The thalidomide disaster, lessons from the past. InTeratogenicity Testing. 2013; 575-586. Humana Press, Totowa, NJ.
  10. Kallen B. Maternal drug use in early pregnancy and infant cardiovascular defect. Reproductive Toxicology . 2003;17(3):255-261.
  11. Källén B, Otterblad Olausson P, Danielsson B. Is erythromycin therapy teratogenic in humans?. Reproductive Toxicology . 2005;20(2):209-214.
  12. Källén B, Danielsson B. Fetal safety of erythromycin. An update of Swedish data. European Journal of Clinical Pharmacology. 2013;70(3):355-360.
  13. Fan H, Gilbert R, O’Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ . 2020;m331.
  14. Tellem R, Shechtman S, Arnon J. Pregnancy outcome after gestational exposure to the new macrolides: a prospective controlled cohort study.Reproductive Toxicology . 2005; 20: 484-485.
  15. Bar-Oz B, Diav-Citrin O, Shechtman S, Tellem R, Arnon J, Francetic I et al. Pregnancy outcome after gestational exposure to the new macrolides: A prospective multi-center observational study.European Journal of Obstetrics & Gynecology and Reproductive Biology . 2008;141(1):31-34.
  16. Cooper WO, Hernandez‐Diaz S, Arbogast PG, Dudley JA, Dyer SM, Gideon PS, Hall KS, Kaltenbach LA, Ray WA. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatric and perinatal epidemiology . 2009;23(1):18-28.
  17. Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Archives of pediatrics & adolescent medicine . 2009;163(11):978-85.
  18. Nordeng H, Romøren M, Lindbæk M. Safety of macrolides during pregnancy—With special focus on erythromycin and congenital heart malformations. Reproductive Toxicology . 2010;2(30):227.
  19. Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin–a population‐based register study from Norway. British journal of clinical pharmacology . 2012;74(6):1053-62.
  20. Bar-Oz B, Weber-Schoendorfer C, Berlin M, Clementi M, Di Gianantonio E, de Vries L, De Santis M, Merlob P, Stahl B, Eleftheriou G, Maňáková E. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester. Drug safety . 2012;35(7):589-98.
  21. Lin KJ, Mitchell AA, Yau WP, Louik C, Hernández-Díaz S. Safety of macrolides during pregnancy. American journal of obstetrics and gynecology . 2013;208(3):221-e1.
  22. Andersen JT, Petersen M, Jimenez-Solem E, Rasmussen JN, Andersen NL, Afzal S, Broedbaek K, Hjelvang BR, Køber L, Torp-Pedersen C, Poulsen HE. Trimethoprim use prior to pregnancy and the risk of congenital malformation: a register-based nationwide cohort study.Obstetrics and gynecology international . 2013;2013.
  23. Dinur AB, Koren G, Matok I, Wiznitzer A, Uziel E, Gorodischer R, Levy A. Fetal safety of macrolides. Antimicrobial agents and chemotherapy . 2013;57(7):3307-11.
  24. Bérard A, Sheehy O, Zhao JP, Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population‐based study.Pharmacoepidemiology and drug safety . 2015;24(12):1241-8.
  25. Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. British journal of clinical pharmacology . 2017;83(11):2557-71.
  26. Damkier P, Brønniche LM, Korch-Frandsen JF, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. American journal of obstetrics and gynecology . 2019;221(6):648-e1.
  27. Czeizel AE, Rockenbauer M, Olsen J, SØRENSEN HT. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta obstetricia et gynecologica Scandinavica . 2000;79(3):234-7.
  28. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reproductive Toxicology . 1999;13(6):531-6.
  29. Mallah N, Tohidinik HR, Etminan M, Figueiras A, Takkouche B. Prenatal Exposure to Macrolides and Risk of Congenital Malformations: A Meta-Analysis. Drug safety . 2019;12:1-1.
  30. Khoury MJ, Moore CA, James LM, Cordero JF. The interaction between dysmorphology and epidemiology: methodologic issues of lumping and splitting. Teratology . 1992;45(2):133-8.
  31. EUROCAT guide 1.4 reference documents[Internet]. 2018 [cited 1 June 2020]. Available from: https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/Full_Guide_1_4_version_28_DEC2018.pdf
  32. de Jong-van den Berg LT, Bakker MK, Dolk H. EUROmediCAT: European surveillance of safety of medication use in pregnancy.Pharmacoepidemiology and Drug Safety . 2011;20(S1):S46-7.
  33. Greenlees R, Neville A, Addor MC, Amar E, Arriola L, Bakker M, Barisic I, Boyd PA, Calzolari E, Doray B, Draper E. Paper 6: EUROCAT member registries: organization and activities. Birth Defects Research Part A: Clinical and Molecular Teratology. 2011;91(S1):S51-100.
  34. Bakker M, De Jonge L. EUROCAT Special Report: Sources of information on medication use in pregnancy. EUROCAT Central Registry . 2014.
  35. Leke AZ. Maternal use and safety of anti-infectives in pregnancy, with special reference to Cameroon (Doctoral dissertation, Ulster University). 2017; Chapter 4, p159.
  36. Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology.Lippincott Williams & Wilkins . 2008.
  37. Hook EB. What kind of controls to use in case control studies of malformed infants: recall bias versus “teratogen nonspecificity” bias. Teratology . 2000;61(5):325-6.
  38. Poletta FA, Camelo JS, Gili JA, Leoncini E, Castilla EE, Mastroiacovo P. Methodological approaches to evaluate teratogenic risk using birth defect registries: advantages and disadvantages. PloS one . 2012;7(10).
  39. Webster R, Leishman D, Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes.Current opinion in drug discovery & development . 2002;5(1):116-26.
  40. Danielsson C, Brask J, Sköld AC, Genead R, Andersson A, Andersson U, Stockling K, Pehrson R, Grinnemo KH, Salari S, Hellmold H. Exploration of human, rat, and rabbit embryonic cardiomyocytes suggests K-channel block as a common teratogenic mechanism. Cardiovascular research . 2013;97(1):23-32.
  41. Davies MP, An RH, Doevendans P, Kubalak S, Chien KR, Kass RS. Developmental changes in ionic channel activity in the embryonic murine heart. Circulation research . 1996;78(1):15-25.
  42. Wang L, Feng ZP, Kondo CS, Sheldon RS, Duff HJ. Developmental changes in the delayed rectifier K+ channels in mouse heart. Circulation research . 1996;79(1):79-85.
  43. Abrahamsson C, Palmer M, Ljung B, Duker G, Bäärnhielm C, Carlsson L, Danielsson B. Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. Cardiovascular research . 1994;28(3):337-44.
  44. Jaffee OC. Hemodynamic factors in the development of the chick embryo heart. The Anatomical Record . 1965;151(1):69-75.
  45. Hill AB. The environment and disease: association or causation?.Proc R Soc Med. 1965;58: 295-300.
  46. Louik C, Werler MM, Mitchell AA. Erythromycin use during pregnancy in relation to pyloric stenosis. American journal of obstetrics and gynecology . 2002;186(2):288-90.
  47. Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ, Wohlfahrt J, Melbye M. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study.Bmj . 2014;348:g1908.
  48. Cooper WO, Ray WA, Griffin MR. Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis.Obstetrics & Gynecology . 2002 Jul 1;100(1):101-6.
  49. Fan H, Li L, Wijlaars L, Gilbert RE. Associations between use of macrolide antibiotics during pregnancy and adverse child outcomes: A systematic review and meta-analysis. PloS one . 2019;14(2).
  50. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Lippincott Williams & Wilkins . 2012.
  51. Karabulut AK, Uysal II, Acar H, Fazliogullari Z. Investigation of developmental toxicity and teratogenicity of macrolide antibiotics in cultured rat embryos. Anatomia, histologia, embryologia. 2008 Oct;37(5):369-75.
  52. Medicines & Healthcare Products Regulatory Agency. Summary of Product Characteristics: Clarithromycin 500mg film-coated tablets. 2019 [cited 1 June 2020]. Available from: http://www.hpra.ie/img/uploaded/swedocuments/Licence_PA1347-068-002_13112019125315.pdf.
  53. Joint Formulary Committee. BNF 77 (British National Formulary) March 2019. Pharmaceutical Press; 2019.
  54. The Swedish Medical Products Agency. [Erythromycin should be avoided during early pregnancy]. 2006. [cited 1 June 2020]. https://lakemedelsverket.se/Alla-nyheter/NYHETER-2005/Erytromycin-bor-undvikas-under-tidiggraviditet/.
  55. Garne E, Dolk H, Loane M, Eurocat PA. EUROCAT website data on prenatal detection rates of congenital anomalies.2010.
  56. Petersen I, Gilbert R, Evans S, Ridolfi A, Nazareth I. Oral antibiotic prescribing during pregnancy in primary care: UK population-based study. Journal of antimicrobial chemotherapy.2010;65(10):2238-46.
  57. de Jonge L, Garne E, Gini R, Jordan SE, Klungsoyr K, Loane M, Neville AJ, Pierini A, Puccini A, Thayer DS, Tucker D. Improving information on maternal medication use by linking prescription data to congenital anomaly registers: a EUROmediCAT study. Drug safety . 2015;38(11):1083-93.